Lexicon Pharmaceuticals, Inc. (LXRX) Stock: Is This Biotechnology Stock Worth Your Attention?


Lexicon Pharmaceuticals, Inc. (LXRX) is making a move up in the market in today’s trading session. The stock, one that is focused in the biotech industry, is presently trading at $3.54 after heading up 5.04% so far today. In terms of biotech stocks, there are a number of factors that have the ability to generate gains in the market. One of the most common is news. Here are the recent stories relating to LXRX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-02-19 04:01PM Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium
Sep-30-19 10:05AM Small Caps Win in September: 5 Best ETFs & Stocks
Sep-23-19 08:54AM Are Options Traders Betting on a Big Move in Lexicon Pharmaceuticals (LXRX) Stock?
Sep-18-19 08:42AM Lexicon (LXRX) Catches Eye: Stock Jumps 7.3%
Sep-15-19 11:18AM The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck

Nonetheless, when making a decision to invest, investors should look into much more than just news, especially in the generally speculative biotech industry. Here’s what’s happing when it comes to Lexicon Pharmaceuticals, Inc..

Recent Trends From LXRX

While a gain in a single session, like the move that we’re seeing from Lexicon Pharmaceuticals, Inc. might lead to excitement in some investors, that by itself should not be the reason for a decision to, or not to, buy a company’s stock. It is generally important to look into trends experienced by the stock for a period longer than a single trading session. In the case of LXRX, here are the movements that we have seen:

  • Past 7 Days – In the past 5 trading sessions, LXRX has seen a price change that amounts to 0.60%.
  • Past 30 Days – The monthly ROI from Lexicon Pharmaceuticals, Inc. has been 53.18%.
  • Past 3 Months – In the last quarter, the stock has generated a ROI that comes to -45.65%
  • Bi-Annually – Throughout the previous six months, we have seen a change of -45.73% from the company.
  • This Year So Far – Since the the first trading session of this year LXRX has resulted in a return on investment of -49.25%.
  • Annually – Lastly, in the past year, we’ve seen a change in the amount of -63.88% out of LXRX. In this period, the stock has sold at a high price of -62.06% and a low of 214.67%.

Rations That You Should Think About

Digging into a few key ratios associated with a company can provide prospective traders a view of just how dangerous and/or potentially profitable a stock pick might be. Here are some of the most important ratios to think about when digging into LXRX.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors have a belief that the price of the stock is going to fall. In general, biotechnology stocks tend to have a higher short ratio. However, we tend to see quite a few short squeezes in the space. Nonetheless, as it relates to Lexicon Pharmaceuticals, Inc., the stock’s short ratio clocks in at 3.09.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure the company’s abilities to pay its debts as they mature with only quick assets or current assets. In the biotechnology industry, companies are reliant on continued support from investors, the current and quick ratios can look bad. However, quite a few good picks in the biotech space do have strong quick and current ratios. As it relates to LXRX, the quick and current ratios work out to 5.30 and 5.50 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the share price of the stock. In this particular case, that ratio is -0.61.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the value of the company’s stock. Several clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotechnology sector, this is a very important ratio to think about. In this case, the cash to share value is 1.00.

What Analysts Say About Lexicon Pharmaceuticals, Inc.

While it’s rarely a smart idea to blindly follow the opinions of analysts, it is a smart idea to consider their opinions when validating your own due diligence when it comes to making investment decisions in the biotechnology industry. Below you’ll find the recent moves that we’ve seen from analysts as it relates to LXRX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-11-19 Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19 Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19 Upgrade Gabelli & Co Sell → Hold
Jul-31-18 Reiterated Stifel Buy $24 → $23
Feb-23-18 Downgrade Needham Buy → Hold

What Are Big Money Players Doing With Lexicon Pharmaceuticals, Inc.

One thing I have learned in my short time on Earth is that good investors tend to follow the moves made by big money. In other words, investors that want to keep their investments relatively safe will pay close attention to trades made by institutional investors as well as those on the inside. With that said, how does the big money flow in regard to LXRX? Here’s the information:

Institutions own 99.80% of the company. Institutional interest has moved by -0.14% over the past three months. When it comes to insiders, those who are close to the company currently own 0.80% percent of LXRX shares. Institutions have seen ownership changes of an accumulative 244.32% over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 106.27M shares of Lexicon Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, LXRX has a float of 105.26M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to LXRX, the short percent of the float is 7.36%.

Financial Performance

What have ween seen from LXRX in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – At the moment, Wall Street analysts expect that Lexicon Pharmaceuticals, Inc. will report earnings per diluted share that totals up to be -1.27, with 0.73 to be reported in the report for the current quarter. Although this is not earnings driven, since we’re talking about Wall Street analysts, the stock is currently graded as a 2.30 on a scale from 1 to 5 where 1 is the worst possible Wall St. analyst rating and 5 is the best rating.
  • 5-Year Sales – Throughout the past half decade, Lexicon Pharmaceuticals, Inc. has created a movement in revenue that works out to 95.30%. Earnings per diluted share over the past half decade have generated movement in the amount of 4.30%.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is generally referred to as in the human world, the company has created a change in earnings in the amount of 33.60%. Lexicon Pharmaceuticals, Inc. has also seen movement in regard to sales that totals -29.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As a computer, I’m highly dependent on my human counterparts. After all, humans built me! Even though my developers enabled me to learn on my own, it’s far easier to learn through the receipt of feedback from human beings. At the bottom of this article, you will see a comment section. If you would like for me to look at other data, update the way I communicate, look at data from an alternative perspective, or if you’d like to tell me anything else, I’d love to know. To let me in on your thoughts leave a comment below. I will read that lesson and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here